Delivery of oligonucleotide-based therapeutics: challenges and opportunities.

Hammond SM, Aartsma-Rus A, Alves S, Borgos SE, Buijsen RAM, Collin RWJ, Covello G, Denti MA, Desviat LR, Desviat LR, Echevarría L, Foged C, Gaina G, Gaina G, Garanto A, Goyenvalle AT, Guzowska M, Holodnuka I, Jones DR, Krause S, Lehto T, Montolio M, Van Roon-Mom W, Arechavala-Gomeza V. · 2021

Read Delivery of oligonucleotide-based therapeutics: challenges and opportunities. by Hammond SM, Aartsma-Rus A, Alves S, Borgos SE, Buijsen RAM, Collin RWJ, Covello G, Denti MA, Desviat LR, Desviat LR, Echevarría L, Foged C, Gaina G, Gaina G, Garanto A, Goyenvalle AT, Guzowska M, Holodnuka I, Jones DR, Krause S, Lehto T, Montolio M, Van Roon-Mom W, Arechavala-Gomeza V. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8033518.txt.

Description

Hammond and co-authors survey the delivery problem facing oligonucleotide-based therapeutics. These drugs steer gene expression, and development has sped up sharply. Eleven products built on antisense oligonucleotides, aptamers, or small interfering RNAs are already marketed. Better chemistry has improved drug properties and cut costs. But getting the molecules into target tissues remains the main hurdle.

The review covers the methods built to cross biological barriers. Conjugates and nanoparticles have changed the game for several diseases. Other targets still await their breakthrough delivery route. The authors describe the model systems used to test new carriers. Safety questions and regulatory demands on synthetic chemistries follow. The closing gap is translation: turning lab success into clinic-ready drugs.

Catalog record

CREATORHammond SM, Aartsma-Rus A, Alves S, Borgos SE, Buijsen RAM, Collin RWJ, Covello G, Denti MA, Desviat LR, Desviat LR, Echevarría L, Foged C, Gaina G, Gaina G, Garanto A, Goyenvalle AT, Guzowska M, Holodnuka I, Jones DR, Krause S, Lehto T, Montolio M, Van Roon-Mom W, Arechavala-Gomeza V.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE120 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC8033518

Browse the full library · About the Tower of Babel